Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
January 25, 2017
- Boy Develops ADEM after DT Vaccine Shot, No Label Change for Now: Panel
January 25, 2017
- MHLW to Launch New Framework for Dialogue with Pharma Industry
January 24, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- MHLW Advisory Committee to Review Sanofi’s VEGF Inhibitor on Feb. 3
January 24, 2017
- PMDA Risk Communication Update for Atarax, Zelboraf
January 23, 2017
- MHLW Asks Pref. Govt to Conduct On-Site Inspections for Pharmacies, Wholesalers: Minister
January 23, 2017
- Correcting Regional Disparities in Generic Use Important for Achieving Govt’s Targets: Health Policy Bureau Chief
January 23, 2017
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
- MHLW to Take Prompt Action on Counterfeit Issue: Bureau Chief
January 20, 2017
- Details of Approvals to Be Provided to Prefectures Prior to Unannounced Inspections: MHLW Official
January 20, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
- MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda
January 17, 2017
- MHLW Task Force on “Data Health” to Compile Report by Summer
January 16, 2017
- PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
- Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021
January 13, 2017
- MHLW Panel on AI Use in Healthcare Boots Up
January 13, 2017
- Projection-Based Price Cuts, Instead of Ex-Post Reviews, Mooted for New Quarterly Scheme
January 12, 2017
- MHLW Wants Specific Plan by May for Four-Times Yearly Price Review of Indication-Added Drugs
January 12, 2017
- Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions
January 12, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…